Exploring reduced pulmonary exacerbation rates in cystic fibrosis: a pandemic or modulator effect?
Public health measures imposed during the pandemic resulted in a reduction in the number of PEx for both countries; however, the impact of ETI on reducing the rate of PEx was more than double the effect of the COVID-19 pandemic.
Authors
- Xiayi Ma (ORCID: https://orcid.org/0000-0003-3504-7637)
- Sanja Stanojevic (ORCID: https://orcid.org/0000-0001-7931-8051)
- Bradley S. Quon (ORCID: https://orcid.org/0000-0003-1785-3870)
- Ranjani Somayaji (ORCID: https://orcid.org/0000-0003-3731-9675)
- Kathleen J. Ramos (ORCID: https://orcid.org/0000-0002-2309-368X)
- Christopher H. Goss (ORCID: https://orcid.org/0000-0001-8602-0309)
- Elizabeth A. Cromwell (ORCID: https://orcid.org/0000-0002-5106-0607)
- A. Faro
- Alex Elbert
- Anne L. Stephenson (ORCID: https://orcid.org/0000-0002-4529-5653)
- Jenna Sykes (ORCID: https://orcid.org/0000-0002-3282-9361)
- Jonathan Todd (ORCID: https://orcid.org/0000-0001-6396-2379)
- Bruce C. Marshall
- Josh Ostrenga
Institutions
- St. Michael's Hospital (CA)
- Dalhousie University (CA)
- University of British Columbia (CA)
- University of Calgary (CA)
- University of Washington (US)
- Cystic Fibrosis Foundation (US)
Publication Details
- Journal
- ERJ Open Research
- Published
- 2025-05-08
- DOI
- https://doi.org/10.1183/23120541.00111-2025
- Citations
- 2
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- American Thoracic Society
- Cystic Fibrosis Foundation Therapeutics
- Chiesi Farmaceutici
- European Respiratory Society
- Seattle Children's Research Institute
- Vertex Pharmaceuticals
- Cystic Fibrosis Canada